115 related articles for article (PubMed ID: 28592703)
1. Real-Time Transferrin-Based PET Detects MYC-Positive Prostate Cancer.
Aggarwal R; Behr SC; Paris PL; Truillet C; Parker MFL; Huynh LT; Wei J; Hann B; Youngren J; Huang J; Premasekharan G; Ranatunga N; Chang E; Gao KT; Ryan CJ; Small EJ; Evans MJ
Mol Cancer Res; 2017 Sep; 15(9):1221-1229. PubMed ID: 28592703
[TBL] [Abstract][Full Text] [Related]
2. Applying ⁸⁹Zr-Transferrin To Study the Pharmacology of Inhibitors to BET Bromodomain Containing Proteins.
Doran MG; Carnazza KE; Steckler JM; Spratt DE; Truillet C; Wongvipat J; Sawyers CL; Lewis JS; Evans MJ
Mol Pharm; 2016 Feb; 13(2):683-8. PubMed ID: 26725682
[TBL] [Abstract][Full Text] [Related]
3. Annotating MYC status with 89Zr-transferrin imaging.
Holland JP; Evans MJ; Rice SL; Wongvipat J; Sawyers CL; Lewis JS
Nat Med; 2012 Oct; 18(10):1586-91. PubMed ID: 23001181
[TBL] [Abstract][Full Text] [Related]
4. (68)Ga-radiopharmaceuticals for PET imaging of infection and inflammation.
Kumar V; Boddeti DK
Recent Results Cancer Res; 2013; 194():189-219. PubMed ID: 22918761
[TBL] [Abstract][Full Text] [Related]
5. Imaging Hepatocellular Carcinoma With
Mari Aparici C; Behr SC; Seo Y; Kelley RK; Corvera C; Gao KT; Aggarwal R; Evans MJ
Mol Imaging; 2017; 16():1536012117723256. PubMed ID: 28893116
[TBL] [Abstract][Full Text] [Related]
6. Relative copy number gain of MYC in diagnostic needle biopsies is an independent prognostic factor for prostate cancer patients.
Ribeiro FR; Henrique R; Martins AT; Jerónimo C; Teixeira MR
Eur Urol; 2007 Jul; 52(1):116-25. PubMed ID: 17070983
[TBL] [Abstract][Full Text] [Related]
7. Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy.
Morigi JJ; Stricker PD; van Leeuwen PJ; Tang R; Ho B; Nguyen Q; Hruby G; Fogarty G; Jagavkar R; Kneebone A; Hickey A; Fanti S; Tarlinton L; Emmett L
J Nucl Med; 2015 Aug; 56(8):1185-90. PubMed ID: 26112024
[TBL] [Abstract][Full Text] [Related]
8. Loss of p53 and c-myc overrepresentation in stage T(2-3)N(1-3)M(0) prostate cancer are potential markers for cancer progression.
Qian J; Hirasawa K; Bostwick DG; Bergstralh EJ; Slezak JM; Anderl KL; Borell TJ; Lieber MM; Jenkins RB
Mod Pathol; 2002 Jan; 15(1):35-44. PubMed ID: 11796839
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic Efficacy of (68)Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer.
Maurer T; Gschwend JE; Rauscher I; Souvatzoglou M; Haller B; Weirich G; Wester HJ; Heck M; Kübler H; Beer AJ; Schwaiger M; Eiber M
J Urol; 2016 May; 195(5):1436-1443. PubMed ID: 26682756
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous
Eiber M; Weirich G; Holzapfel K; Souvatzoglou M; Haller B; Rauscher I; Beer AJ; Wester HJ; Gschwend J; Schwaiger M; Maurer T
Eur Urol; 2016 Nov; 70(5):829-836. PubMed ID: 26795686
[TBL] [Abstract][Full Text] [Related]
11. Dual-Modality Imaging of Prostate Cancer with a Fluorescent and Radiogallium-Labeled Gastrin-Releasing Peptide Receptor Antagonist.
Zhang H; Desai P; Koike Y; Houghton J; Carlin S; Tandon N; Touijer K; Weber WA
J Nucl Med; 2017 Jan; 58(1):29-35. PubMed ID: 27516447
[TBL] [Abstract][Full Text] [Related]
12. Fluorescent in situ hybridization study of c-myc oncogene copy number in prostate cancer.
Mark HF; Samy M; Santoro K; Mark S; Feldman D
Exp Mol Pathol; 2000 Feb; 68(1):65-9. PubMed ID: 10640455
[TBL] [Abstract][Full Text] [Related]
13. Advancement of MR and PET/MR in Prostate Cancer.
Lindenberg L; Ahlman M; Turkbey B; Mena E; Choyke P
Semin Nucl Med; 2016 Nov; 46(6):536-543. PubMed ID: 27825433
[TBL] [Abstract][Full Text] [Related]
14. Preclinical comparison of Al18F- and 68Ga-labeled gastrin-releasing peptide receptor antagonists for PET imaging of prostate cancer.
Chatalic KL; Franssen GM; van Weerden WM; McBride WJ; Laverman P; de Blois E; Hajjaj B; Brunel L; Goldenberg DM; Fehrentz JA; Martinez J; Boerman OC; de Jong M
J Nucl Med; 2014 Dec; 55(12):2050-6. PubMed ID: 25413139
[TBL] [Abstract][Full Text] [Related]
15. N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer.
Dardenne E; Beltran H; Benelli M; Gayvert K; Berger A; Puca L; Cyrta J; Sboner A; Noorzad Z; MacDonald T; Cheung C; Yuen KS; Gao D; Chen Y; Eilers M; Mosquera JM; Robinson BD; Elemento O; Rubin MA; Demichelis F; Rickman DS
Cancer Cell; 2016 Oct; 30(4):563-577. PubMed ID: 27728805
[TBL] [Abstract][Full Text] [Related]
16. Copy number alterations of c-MYC and PTEN are prognostic factors for relapse after prostate cancer radiotherapy.
Zafarana G; Ishkanian AS; Malloff CA; Locke JA; Sykes J; Thoms J; Lam WL; Squire JA; Yoshimoto M; Ramnarine VR; Meng A; Ahmed O; Jurisica I; Milosevic M; Pintilie M; van der Kwast T; Bristow RG
Cancer; 2012 Aug; 118(16):4053-62. PubMed ID: 22281794
[TBL] [Abstract][Full Text] [Related]
17. Clinical Translation of a Dual Integrin αvβ3- and Gastrin-Releasing Peptide Receptor-Targeting PET Radiotracer, 68Ga-BBN-RGD.
Zhang J; Niu G; Lang L; Li F; Fan X; Yan X; Yao S; Yan W; Huo L; Chen L; Li Z; Zhu Z; Chen X
J Nucl Med; 2017 Feb; 58(2):228-234. PubMed ID: 27493267
[TBL] [Abstract][Full Text] [Related]
18. PSA-stratified detection rates for [
Derlin T; Schmuck S; Juhl C; Zörgiebel J; Schneefeld SM; Walte ACA; Hueper K; von Klot CA; Henkenberens C; Christiansen H; Thackeray JT; Ross TL; Bengel FM
Eur J Nucl Med Mol Imaging; 2018 Jun; 45(6):913-922. PubMed ID: 29308527
[TBL] [Abstract][Full Text] [Related]
19. Noninvasive Measurement of mTORC1 Signaling with
Truillet C; Cunningham JT; Parker MFL; Huynh LT; Conn CS; Ruggero D; Lewis JS; Evans MJ
Clin Cancer Res; 2017 Jun; 23(12):3045-3052. PubMed ID: 28007777
[No Abstract] [Full Text] [Related]
20. Combined MYC Activation and Pten Loss Are Sufficient to Create Genomic Instability and Lethal Metastatic Prostate Cancer.
Hubbard GK; Mutton LN; Khalili M; McMullin RP; Hicks JL; Bianchi-Frias D; Horn LA; Kulac I; Moubarek MS; Nelson PS; Yegnasubramanian S; De Marzo AM; Bieberich CJ
Cancer Res; 2016 Jan; 76(2):283-92. PubMed ID: 26554830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
